



dysfunction: new treatment approach using once daily tadalafil. *Urologie A* 2009; 48(11): 1320–1329.

16. Ismail EA, El-Sakka AI. Innovative trends and perspectives for erectile dysfunction treatment: A systematic review. *Arab J Urol*. 2016;14(2): 84–93.

17. Fink HA, MacDonald R, Rutks IR, Wilt TJ. Trazodone for erectile dysfunction: a systematic review and meta-analysis. *BJU Int*. 2003. 92(4): 441–446.

18. Rezaee ME, Gross MS. Are We Overstating the Risk of Priapism With Oral Phosphodiesterase Type 5 Inhibitors?. *J Sex Med*. 2020;17(8): 1579–1582.

19. Šrámková T. Terapie erektilní dysfunkce dle Guidelines Evropské urologické asociace. *Kardiol Rev Int Med* 2014; 16(4): 288–293.

20. Derouet H, Weirauch A, Bewermeier H. Prostaglandin E1 (PGE1) in diagnosis and long-term therapy of erectile dysfunction. *Urologie A*. 1996; 35(1): 62–67.

21. Lee S, Lee J, Choi YW. Design and evaluation of prostaglandin E1 (PGE1) intraurethral liquid formulation employing self-microemulsifying drug delivery system (SMEDDS) for erectile dysfunction treatment. *Biol Pharm Bull*. 2008. 31(4): 668–672.

22. Zámečník L, Novák J. Nový typ léčby poruch erekce na trhu v ČR – aplikace alprostadilu ve formě krému. *Urol. praxi* 2016; 17(5): 217–222.

23. Ritchie R, Sullivan M. Endothelins & erectile dysfunction. *Pharmacolog. Res*. 2011; 63: 496–501.

24. Khan MA, Calvert RC, Sullivan ME, et al. Normal and pathological erectile function: the potential clinical role of endothelin-1 antagonists. *Curr Drug Targets*. 2000; 1(3): 247–260.

25. Borrelli F, Colalto C, Delfino DV, et al. Herbal Dietary Supplements for Erectile Dysfunction: A Systematic Review and Meta-Analysis. *Drugs*. 2018, 78(6): 643–673.

26. Shamloul R. Natural Aphrodisiacs. *J. Sex. Med*. 2010; 7: 39–49.

27. Jackson G, Boon N, Eardely I, et al. Erectile dysfunction and coronary artery disease prediction: evidence – based Guidance and consensus. *Int J Clin Pract*. 2010; 64(7): 848–857.

28. De Busc R, Drory R, Goldstein I, et al. Management of sexual dysfunction in patients with cardiovascular disease: Recommendations of the Princeton Consensus panel. *Am J Cardiol*. 2000; 86: 175–181.

29. Phé V, Roupret M. Erectile dysfunction and diabetes. A review of the current evidence-based medicine and a synthesis of the main available therapies. *Diabetes Metab*. 2012; 38: 1–13.

30. Morales AM, Hatzichristou D, Lladós JR, et al. Community Pharmacy Detection of Erectile Dysfunction in Men with Risk Factors or Who Seek Treatment or Advice but Lack a Valid Prescription. *The Journal of Sexual Medicine*. 2013, 10(9): 2303–2311.

31. Taylor DG, Giuliano F, Hackett G, et al. The pharmacist's role in improving the treatment of erectile dysfunction and its underlying causes. *Research in Social and Administrative Pharmacy*. 2019; 15(5): 591–599

32. Oakley N, Moore KTH. Vacuum devices in erectile dysfunction: indications and efficacy. *BJU International*. 1998; 82(5): 673–681.

33. Odborné poradenství v lékárnách. [online]. Česká lékárnická komora [cit. 2020-10-28]. Dostupné z: <https://www.sukl.cz/modules/medication/search.php>.